Abstract: A method for analyzing a test agent to determine whether or not the test agent affects electrical activity of a cardiomyocyte is disclosed. The method includes: i) providing an induced pluripotent stem cell (iPSC) derived cardiomyocyte (iPSC-DM) that has been modified to contain an oligonucleotide that increases iPSC-DM IKr; ii) measuring IKr and action potential of the iPSC-DM of i); subsequently iii) contacting the iPSC-DM of i) with the test agent; and iv) measuring IKr and action potential of the iPSC-DM that has been contacted with the test agent; and determining a difference between the IKr and action potential of ii) and the IKr and the action potential of iv) to indicate the test agent affects the electrical activity of the cardiomyocyte, or determining the same IKr and action potential of ii) and iv) to indicate the test agent does not adversely affect the electrical activity of the cardiomyocyte.

Abstract: Systems and methods are provided for improving action potential morphology in iPSC-derived cardiac myocytes and utilizing such myocytes. Improved morphology may include, for example, physiological resting membrane potentials. Membrane voltages of the myocyte are measured and a synthetic inward rectifying current is applied to the myocyte based on the membrane voltage.

Abstract: Systems and methods are provided for improving action potential morphology in iPSC-derived cardiac myocytes and utilizing such myocytes. Improved morphology may include, for example, physiological resting membrane potentials. Membrane voltages of the myocyte are measured and a synthetic inward rectifying current is applied to the myocyte based on the membrane voltage.